
UK-based Neurovalens already markets Modius Lean, a wearable that stimulates the vestibular system through electrodes behind the ears. Last year, it received FDA authorization to support weight management. A clinical trial involving 241 participants found significant reductions in visceral fat, although the study missed its primary weight-loss endpoints.
The FDA granted de novo classification to Neurovalens' Modius Spero just two days ago, making it the world's first neuromodulation device authorized to treat symptoms associated with PTSD. The device delivers electrical vestibular system stimulation behind each ear for 30 minutes daily, targeting deep brain regions associated with stress response. Neurovalens now holds FDA authorizations across four indications: insomnia, anxiety, weight management, and PTSD. See the Double Click section below for a closer look.